{"title":"Association of Gleason Patterns with α-Methylacyl-Coa Racemase (AMACR) Immunohistochemistry Reaction.","authors":"Mihriban Gürbüzel, Berna Eriten, Meryem Yüvrük, Gülce S Yildiz, Dilek Yavuzer","doi":"10.7754/Clin.Lab.2024.241202","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Prostate cancer, with a reported prevalence of 35 per hundred thousand in Türkiye, ranks third among the most frequently encountered cancers worldwide. In incisional needle biopsies, it is a challenge to identify malignant glands that are very few or sometimes mixed within benign changes such as adenosis and atrophy. AMACR is a marker that is seen to have a higher expression in the malignant lesions of the prostate compared to a normal prostate. In this study, we aimed to retrospectively report the cases where we used this marker, for which we believe that it strongly supports findings of malignancy in our daily routine, and present our findings along with other findings in the literature.</p><p><strong>Methods: </strong>We searched prostate needle biopsy cases in which AMACR was tested as an immunohistochemistry method between July 2022 and June 2023 on the digital system of the hospital. The study included 104 cases consisting of the diagnoses of prostate adenocarcinoma and ASAP (atypical small acinar proliferation), which included 8 HGPIN cases. Patient ages were also recorded. The cases were reevaluated based on their staining grades, rated as none: 0, weak: 1, moderate: 2, and strong: 3, in addition to the areas of staining in percentages. The collected data were analyzed using the SPSS (Statistical Package for the Social Sciences) for Windows 22.0 program.</p><p><strong>Results: </strong>All cases were positive for AMACR, and the prevalence was 100%. The AMACR staining grades were moderate by 44.9% in Gleason pattern 3 (P3) cases and 49.1% in Gleason pattern 4 (P4) cases, whereas most Gleason pattern 5 (P5) cases had strong staining at a rate of 63.2%. Weak staining was more frequently encountered in the eight ASAP and eight HGPIN cases, whereas no strong staining was observed in any ASAP case.</p><p><strong>Conclusions: </strong>In the comparisons of patient ages and Gleason patterns, no significant difference was found in terms of staining grades (p > 0.05). There was a 53.6% positive correlation between P3 and P4 staining grades (p < 0.05). There was also an 86.2% positive correlation between P5 and P4 staining grades (p < 0.05).</p>","PeriodicalId":10384,"journal":{"name":"Clinical laboratory","volume":"71 6","pages":""},"PeriodicalIF":0.7000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical laboratory","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.7754/Clin.Lab.2024.241202","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Prostate cancer, with a reported prevalence of 35 per hundred thousand in Türkiye, ranks third among the most frequently encountered cancers worldwide. In incisional needle biopsies, it is a challenge to identify malignant glands that are very few or sometimes mixed within benign changes such as adenosis and atrophy. AMACR is a marker that is seen to have a higher expression in the malignant lesions of the prostate compared to a normal prostate. In this study, we aimed to retrospectively report the cases where we used this marker, for which we believe that it strongly supports findings of malignancy in our daily routine, and present our findings along with other findings in the literature.
Methods: We searched prostate needle biopsy cases in which AMACR was tested as an immunohistochemistry method between July 2022 and June 2023 on the digital system of the hospital. The study included 104 cases consisting of the diagnoses of prostate adenocarcinoma and ASAP (atypical small acinar proliferation), which included 8 HGPIN cases. Patient ages were also recorded. The cases were reevaluated based on their staining grades, rated as none: 0, weak: 1, moderate: 2, and strong: 3, in addition to the areas of staining in percentages. The collected data were analyzed using the SPSS (Statistical Package for the Social Sciences) for Windows 22.0 program.
Results: All cases were positive for AMACR, and the prevalence was 100%. The AMACR staining grades were moderate by 44.9% in Gleason pattern 3 (P3) cases and 49.1% in Gleason pattern 4 (P4) cases, whereas most Gleason pattern 5 (P5) cases had strong staining at a rate of 63.2%. Weak staining was more frequently encountered in the eight ASAP and eight HGPIN cases, whereas no strong staining was observed in any ASAP case.
Conclusions: In the comparisons of patient ages and Gleason patterns, no significant difference was found in terms of staining grades (p > 0.05). There was a 53.6% positive correlation between P3 and P4 staining grades (p < 0.05). There was also an 86.2% positive correlation between P5 and P4 staining grades (p < 0.05).
背景:据报道,前列腺癌在日本的患病率为每10万人中有35人,在全球最常见的癌症中排名第三。在切口穿刺活检中,识别恶性腺体是一个挑战,这些恶性腺体很少或有时混合在良性变化中,如腺病和萎缩。与正常前列腺相比,AMACR在前列腺恶性病变中表达更高。在这项研究中,我们的目的是回顾性报告我们使用该标记的病例,我们认为它有力地支持了我们日常生活中的恶性肿瘤发现,并将我们的发现与文献中的其他发现一起发表。方法:检索该医院数字系统中2022年7月至2023年6月间采用免疫组化方法检测AMACR的前列腺穿刺活检病例。本研究纳入诊断为前列腺癌和ASAP(非典型小腺泡增生)的104例,其中HGPIN 8例。同时记录患者年龄。除了以百分比表示的染色区域外,还根据其染色等级对病例进行重新评估,评分为无:0,弱:1,中度:2和强:3。收集的数据使用SPSS (Statistical Package for The Social Sciences) for Windows 22.0程序进行分析。结果:所有病例均为AMACR阳性,患病率为100%。Gleason 3型(P3)和4型(P4)患者的AMACR染色程度分别为44.9%和49.1%,而大多数Gleason 5型(P5)患者的AMACR染色强度为63.2%。8例ASAP和8例HGPIN患者多见弱染色,而所有ASAP患者均未见强染色。结论:在患者年龄和Gleason模式的比较中,染色分级差异无统计学意义(p < 0.05)。P3与P4染色分级呈正相关(p < 0.05)。P5和P4染色等级之间也有86.2%的正相关(p < 0.05)。
期刊介绍:
Clinical Laboratory is an international fully peer-reviewed journal covering all aspects of laboratory medicine and transfusion medicine. In addition to transfusion medicine topics Clinical Laboratory represents submissions concerning tissue transplantation and hematopoietic, cellular and gene therapies. The journal publishes original articles, review articles, posters, short reports, case studies and letters to the editor dealing with 1) the scientific background, implementation and diagnostic significance of laboratory methods employed in hospitals, blood banks and physicians'' offices and with 2) scientific, administrative and clinical aspects of transfusion medicine and 3) in addition to transfusion medicine topics Clinical Laboratory represents submissions concerning tissue transplantation and hematopoietic, cellular and gene therapies.